Affiliation:
1. Sechenov First Moscow State Medical University (Sechenov University)
Abstract
Introduction. Acute otitis media is a widespread multifactorial disease characterized by inflammatory changes in the mucosa of all parts of the middle ear. One of the most important tasks in the early stages of the disease is adequate anesthesia of patients. The article provides a retrospective assessment of the efficacy (speed of analgesia) and tolerability of topical use of Otipax® (lidocaine + phenazone) in adult patients with acute otitis media before perforation, the timing of its use is justified.Aim. To assess the efficacy and tolerability of topical Otipax® in adult patients with pre-perforated acute otitis media prescribed by a physician in routine practice.Materials and methods. Outpatient maps of 50 adult patients with acute otitis media were analyzed.Results. In almost all 50 patients after the use of Otipax®, the analgesic effect occurred after 3 minutes. The analgesic effect remained on average for 35–40 minutes, then the pain gradually resumed, but in dynamics there was a decrease in its intensity. Hearing loss and ear congestion were initially noted in all patients, by the 3rd visit these complaints persisted, but their intensity was significantly lower, on the 10th day of observation there were no subjectively impaired hearing in any of the patients, which corresponded to acumetric and tuning fork data. The anti-inflammatory effect of Otipax® after a day provided a significant decrease in the intensity and area of hyperemia and infiltration of the eardrum. After 10 days, almost all patients had no otoscopic signs of otitis media. No adverse events were reported during the follow-up period.Conclusions. The use of Otipax® (lidocaine + phenazone) ear drops complies with the clinical guidelines of the Ministry of Health of the Russian Federation in 2021 for the treatment of patients with acute otitis media before perforation, effectively and safely, is the method of choice for reducing ear pain in patients already at the primary appointment.
Reference30 articles.
1. Карнеева ОВ, Гуров АВ, Поляков ДП, Тулупов ДА, Рязанцев СВ, Гагуа АК, Трухин ДВ. Отит средний острый: клинические рекомендации. 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/314_2.
2. Danishyar A, Ashurst JV. Acute Otitis Media. 2023. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://pubmed.ncbi.nlm.nih.gov/29262176/.
3. Esposito S, Bianchini S, Argentiero A, Gobbi R, Vicini C, Principi N. New Approaches and Technologies to Improve Accuracy of Acute Otitis Media Diagnosis. Diagnostics (Basel). 2021;11(12):2392. https://doi.org/10.3390/diagnostics11122392.
4. Scott AM, Clark J, Julien B, Islam F, Roos K, Grimwood K et al. Probiotics for preventing acute otitis media in children. Cochrane Database Syst Rev. 2019;6(6):CD012941. https://doi.org/10.1002/14651858.cd012941.pub2.
5. Jose J, Coatesworth AP, Anthony R, Reilly PG. Life threatening complications after partially treated mastoiditis. BMJ. 2003;327(7405):41–42. https://doi.org/10.1136/bmj.327.7405.41.